Cheng Du Sheng Nuo Biotec Co. Ltd. A (SHG:688117) — Market Cap & Net Worth
Market Cap & Net Worth: Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117)
Cheng Du Sheng Nuo Biotec Co. Ltd. A (SHG:688117) has a market capitalization of $553.88 Million (CN¥3.79 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #11823 globally and #3391 in its home market, demonstrating a 5.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cheng Du Sheng Nuo Biotec Co. Ltd. A's stock price CN¥24.05 by its total outstanding shares 157385978 (157.39 Million). Also see Cheng Du Sheng Nuo Biotec Co. Ltd. A asset portfolio for a full breakdown of the balance sheet.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Market Cap History: 2021 to 2026
Cheng Du Sheng Nuo Biotec Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $586.73 Million to $553.88 Million (-11.37% CAGR). Also see 688117 operating cash flow for how efficiently the company converts equity into cash flow.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cheng Du Sheng Nuo Biotec Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Cheng Du Sheng Nuo Biotec Co. Ltd. A stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.30x
Cheng Du Sheng Nuo Biotec Co. Ltd. A's market cap is 1.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.82x
Cheng Du Sheng Nuo Biotec Co. Ltd. A's market cap is 11.82 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $586.73 Million | $386.53 Million | $61.25 Million | 1.52x | 9.58x |
| 2022 | $359.75 Million | $395.72 Million | $64.48 Million | 0.91x | 5.58x |
| 2023 | $644.47 Million | $435.02 Million | $70.34 Million | 1.48x | 9.16x |
| 2024 | $591.19 Million | $456.07 Million | $50.02 Million | 1.30x | 11.82x |
Competitor Companies of 688117 by Market Capitalization
Companies near Cheng Du Sheng Nuo Biotec Co. Ltd. A in the global market cap rankings as of September 21, 2026. Review Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cheng Du Sheng Nuo Biotec Co. Ltd. A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #612 globally with a market cap of $44.88 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #612 | GALDERMA GROUP AG | NYSE:GALDY | $44.88 Billion | $38.49 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Cheng Du Sheng Nuo Biotec Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Cheng Du Sheng Nuo Biotec Co. Ltd. A's market cap moved from $586.73 Million to $ 553.88 Million, with a yearly change of -11.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥553.88 Million | -36.36% |
| 2025 | CN¥870.32 Million | +47.21% |
| 2024 | CN¥591.19 Million | -8.27% |
| 2023 | CN¥644.47 Million | +79.14% |
| 2022 | CN¥359.75 Million | -38.69% |
| 2021 | CN¥586.73 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Cheng Du Sheng Nuo Biotec Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $553.88 Million USD |
| MoneyControl | $553.88 Million USD |
| MarketWatch | $553.88 Million USD |
| marketcap.company | $553.88 Million USD |
| Reuters | $553.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more